Refine by MP, party, committee, province, or result type.

Results 46-53 of 53
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  Sure. We have all talked about a few things here. We've talked about the need to identify and set priorities. I think we can all agree that we need a process for identifying them. What are the tools that we are missing? What are the medicines, the diagnostics, the medical devices

October 18th, 2018Committee meeting

Dr. Jason Nickerson

Health committee  Good morning. Thank you for the opportunity to address the committee on this important topic. I am the humanitarian affairs advisor for Doctors Without Borders, or Médecins Sans Frontières, MSF, based here in Ottawa. I am also a respiratory therapist with clinical and public hea

October 18th, 2018Committee meeting

Dr. Jason Nickerson

International Trade committee  We do have an analysis of that, I believe. I don't have the data immediately in front of me. I'd rather not venture a guess, but I can provide that to you.

June 7th, 2016Committee meeting

Jason Nickerson

International Trade committee  I'm not entirely familiar with the context of the statement. I'd prefer to provide a written answer. In our experience, we do see that correlation between stronger intellectual property provisions and higher drug prices. It stands to reason that as you have only one manufacture

June 7th, 2016Committee meeting

Jason Nickerson

International Trade committee  Judit can answer that best.

June 7th, 2016Committee meeting

Jason Nickerson

International Trade committee  Absolutely. I'm actually going to turn it to my colleague, Judit, in New York, who has been following quite closely these conversations that have been held at the World Health Assembly and in many other international fora. So, Judit, I'll ask you to answer.

June 7th, 2016Committee meeting

Jason Nickerson

International Trade committee  As I understand those comments, they are specific to the Canadian context. Our concerns relate more to the countries in the context in which we work. I don't feel I can comment adequately on the analysis of the impact on domestic prices of medicines in Canada. I'm not sure if m

June 7th, 2016Committee meeting

Jason Nickerson

International Trade committee  Thank you for the opportunity to address the committee on this important issue. I'm a humanitarian affairs advisor with Doctors Without Borders/Médecins Sans Frontières. I'm here to present our perspectives regarding the negative impact that the Trans-Pacific Partnership agreeme

June 7th, 2016Committee meeting

Jason Nickerson